Search results
Showing results for
Researchers have found that despite an ongoing trend for a decreasing proportion of males being enrolled in antileishmanial therapeutic efficacy trials over time, there are still 1.8 times as many males as females involved in clinical trials. A new systematic review and meta-analysis suggests that existing knowledge on drug efficacy is derived from a study population that is heavily skewed towards adult males. At the same time, substantially less is known about the optimal treatment response in female patients.
©
Credit: Rama George-Alleyne, World Bank
Louise Thwaites
BSc MBBS MRCP MD DMSMed MLCOM Louise Thwaites - Professor of Experimental Critical Care
